HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,390.00
-90.00 (-2.59%)
Sep 19, 2025, 12:40 PM KST
-2.59%
Market Cap424.03B
Revenue (ttm)108.93B
Net Income (ttm)-77.70B
Shares Out121.85M
EPS (ttm)-654.16
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume269,613
Average Volume418,097
Open3,480.00
Previous Close3,480.00
Day's Range3,380.00 - 3,490.00
52-Week Range3,370.00 - 12,520.00
Beta-0.33
RSI33.92
Earnings DateNov 13, 2025

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.